New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris

Thomas Vogl, Franz Stefan Hartner, Anton Glieder*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Biopharmaceuticals are an integral part of modern medicine and pharmacy. Both, the development and the biotechnological production of biopharmaceuticals are highly cost-intensive and require suitable expression systems. In this review we discuss established and emerging tools for reengineering the methylotrophic yeast Pichia pastoris for biopharmaceutical production. Recent advancements of this industrial expression system through synthetic biology include synthetic promoters to avoid methanol induction and to fine-tune protein production. New platform strains and molecular cloning tools as well as in vivo glycoengineering to produce humanized glycoforms have made P. pastoris an important host for biopharmaceutical production.
Original languageEnglish
Pages (from-to)1094-1101
JournalCurrent Opinion in Biotechnology
Volume24
Issue number6
DOIs
Publication statusPublished - 2013

Fields of Expertise

  • Human- & Biotechnology

Treatment code (Nähere Zuordnung)

  • Review

Fingerprint

Dive into the research topics of 'New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris'. Together they form a unique fingerprint.

Cite this